BeiGene Limited (BGNE): The large (top three) 18.60% BGNE stake has been in the portfolio since their US listing in Q1 2016. Unlike many biotech companies, which are pre-revenue, Incyte has been growing its top and bottom line for years. Nonetheless, BeiGene produces miniature revenues against its $18.7 billion market cap, indicating that investors are betting heavily on the companys long-term prospects. ***Log In or By using this site, you are agreeing to security monitoring and auditing. (k)Jurisdiction. Performance over the past three years has lagged, but it could be a temporary phase for the fund, which, after all, focuses on long-term returns. Its. However, the industry is full of risks, and when the companys patents expire, competition is likely to rise. (c)Subject at all times to Section3(n) below and the other limitations set forth in this Reference ID: 0.bfed655f.1677703966.7fc99eb. BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. N/A BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER OF THE GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC. Amarin Corp plc (AMRN): The original AMRN stake was built in Q3 2016 at prices between ~$2.15 and ~$3.15. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Active, Closed, This describes the type of investor this organization is (e.g. Note: Baker Brothers controls ~29% of the business. 151.252.56.27 There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. Keep reading this article to learn more about Baker Brothers Advisors. Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, Total number of organizations similar to the given organization, Where the organization is headquartered (e.g. Mr. Goller holds a B.S. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. {"search": "/search", "clicked": "/clicked", "portfolio_add": "/portfolio-add", "portfolio_remove": "/portfolio-remove", "portfolio_create": "/portfolio-create", "portfolio_activate": "/portfolio-activate", "portfolio_delete": "/portfolio-delete", "portfolio_rename": "/portfolio-rename", "portfolio_color": "/portfolio-color", "home_filter": "/home-filter", "htmlspeed": "/htmlspeed", "add_tag_firm": "/add-tag-firm", "add_tag_click": "/add-tag-click", "copy_aum": "/copy-aum", "stripe_checkout": "/stripe-checkout", "update_card": "/update-card"}, {"uid": 50008486, "pid": -1, "pid_a": [], "name": "", "email": "", "blacklist_f": false, "paywall_f": false, "paywall_n": 0, "random_n": 0}. The original stake goes back to funding rounds prior to its Q4 2018 IPO. Lists Featuring This Company Early Stage Venture Investors (Top 10K) 10,000 Number of Organizations $63B Total Funding Amount 1,945 Number of Investors Track Private New York Companies (Top 10K) These fundamental metrics include business financials, cash flows, and the merit of its goods and services. value $0.0001 per share. Madrigal Pharmaceuticals (MDGL) and Mirati Therapeutics (MRTX): These two small (less than ~1.10% of the portfolio each) stakes were kept steady this quarter. New York, NY, 10014. If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. The 13F portfolio value remained steady this quarter at $22.77B. Please disable your ad-blocker and refresh. However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. I have no business relationship with any company whose stock is mentioned in this article. Shares plunged by a massive 45%, and they have yet to recover since then. Apellis Pharma (APLS): The small 0.63% APLS stake saw a ~36% increase last quarter at prices between ~$41 and ~$65. Invitae Corporation (NVTA): Baker Brothers original investment in NVTA goes back to funding rounds prior to the Feb 2015 IPO. Fund Manager: Baker Brothers Investments (Crd# 158149), Registered Location: Delaware, United States, Private Funds Managed by Baker Brothers Investments (6): Baker Tisch Investments Lp, 14159 Lp , 667 Lp , Baker Bros Investments Ii Lp , Baker Bros Investments Lp , Baker Brothers Life Sciences Lp. Since then the activity has been minor. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. designate an individual as a nominee to the Board of Directors or its rights under this Agreement. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. 212-339-5600. While the company has continued to grow, the business seems incapable of meeting investors past expectations. Contact Information Fund Manager Baker Brothers Investments Fund Category The stock currently trades at $47.55. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any Click to reveal The company features extraordinary revenue growth, with its 5-year CAGR standing at 40.6%. Thank you for your interest in the U.S. Securities and Exchange Commission. Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics. Major activity in the last decade follows. The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. Broker-Dealer(s): Goldman, Sachs & Co., . Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers . There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals. No delay or omission to Necessary cookies are absolutely essential for the website to function properly. You also have the option to opt-out of these cookies. This analysis is for one-year following each trade, and . address by providing the other party written notice of such change. This website uses cookies to improve your experience while you navigate through the website. The stock currently trades at ~$133. While the companys revenue growth has seemingly stagnated over the past couple of years, it appears that the companys development pipeline remains rather strong. The position was held stable during the quarter. The position is now at 1.23% of the portfolio. These investors may include private investors, venture capital firms, or other investment vehicles. We are EVERSANA. Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. ACADIA Pharmaceuticals focuses on the development and commercialization of small molecule drugs aimed at unmet medical needs in central nervous system disorders. AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. This cookie is set by GDPR Cookie Consent plugin. Note: We do not offer technical support for developing or debugging scripted downloading processes. See how we calculate 13F filing performance here. Its stake in Seattle Genetics is up $1 billion since news of. They add up to ~73% of the portfolio. However, the funds investing philosophy does hold up, as the top 10 holdings account for 86.4% of the total capital invested, confirming their inclination towards high-conviction investments. Ownership. The stock currently trades at ~$153. For more information, please see the SECs Web Site Privacy and Security Policy. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. email address below and choose 'Submit'. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Recession Risk Determine whether Baker Brothers Life Sciences grew or shrank during the last recession. (b)Certain (g)Delays or Omissions. Disclosure: I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. Additionally, the rights set forth in this Section2(c) may With respect to the Observer, the Companys obligations under this Section2(c) are contingent upon such Observers (x)entering into a confidentiality agreement with the Company in a form that is reasonably acceptable to the WHEREAS, the Company and the Investor are parties to that certain Nominating Agreement dated January15, 2021 (the Original [SIGNATURE PAGE TO TSCAN THERAPEUTICS AMENDED While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. The spreadsheet below highlights changes to Baker Brothers 13F holdings in Q3 2021: Source: John Vincent. It invests in the public equity markets of the United States. Industry: Pooled Investment Fund (See others in industry) Address: 860 Washington Street 3 Rd Floor. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. This website uses cookies to improve your experience. Terms of Submission Shares started trading at ~$10 and currently goes for $85.56. Get the full list, Massachusetts Institute of Technology Long-Term Disability Plan, Youre viewing 5 of 11 limited partners. I wrote this article myself, and it expresses my own opinions. (1)person designated at any time and from time to time by the Investor (the Investor Designee); provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in Note: Regulatory filings since the quarter ended show them owning 4.7M shares (15.1% of business) of Entrada Therapeutics (TRDA). This Agreement shall automatically terminate upon the earliest of (i)such time as The stock is now at $87.22, and the stake is at 2.59% of the portfolio. NEW YORK, NY The fund is located in New York, New York and will invest in United States. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) Council Members. This information is available in the PitchBook Platform. Note: 13F filing performance is different than fund performance. I am not receiving compensation for it (other than from Seeking Alpha). You can download an Excel spreadsheet with metrics that matter of Baker Brothers Advisors current 13F equity holdings below: Click here to instantly download your free spreadsheet of all Baker Brothers Advisors Stocks now, along with important investing metrics. Is this happening to you frequently? The stock currently trades at $23.62. Despite the uncertainty surrounding BeiGene, the company has developed into a fully integrated global biotechnology company with operations in China, the United States, Europe, and Australia. Since then, the activity has been minor. Pour plus dinformations, veuillez consulter notre politique de gestion des cookies. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. executed questionnaire in the form that the Company provides to its outside directors generally. [Remainder of page intentionally left blank]. 33. Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. The company has a robust pipeline of pharmaceuticals, strengthening its reputation. (d)Common Stock means shares of the Companys Common Stock, par In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is This cookie is set by GDPR Cookie Consent plugin. Since then, the activity has been minor. (c)Bylaws means the Bylaws of the Company, as may be amended, restated or otherwise modified There was a marginal increase last quarter. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the . Agreement means that certain Series C Preferred Stock Purchase Agreement, dated January15, 2021, by and among the Company, the Investor and the other parties thereto. time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. This Agreement shall be governed by and construed in accordancewith the internal Shares started trading at ~$25 and currently goes for ~$16. Definitions. attendance at such meeting is reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel or (ii)access to such information or attendance at such meeting is reasonably likely to result in a conflict Heron Therapeutics (HRTX): HRTX is a 0.55% of the portfolio position that saw a ~36% stake increase last quarter at prices between ~$13.25 and ~$18.50. We reserve the right to block IP addresses that submit excessive requests. In that regard, the valuation seems compressed. Note: Baker Brothers controls ~6% of the business. Felix Baker '91, PhD '98. DBV Technologies therapies are investigational and not FDA approved. Linda Rosenberg Ach P '12. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. The cookie is used to store the user consent for the cookies in the category "Performance". Angel, Fund of Funds, Venture Capital). Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. That was followed with a ~45% stake increase in Q1 2017 at prices between ~$100 and ~$150. Note: Baker Brothers controls ~13% of the business. The Baker brothers have built a truly special hedge fund. The stock is now at $89.08. Notices shall be effective upon receipt. Blue Sky Digital Outdoor Advertising Fund Fund Data, Sarasin Ie Global Equity Opportunities (Usd) Fund Data, Themelios Ventures Ii-A, L.P. Fund Data. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. $0.0001 per share. The stake goes back to funding rounds prior to their IPO last September. In . H2 2018 saw a stake doubling at prices between ~$3 and ~$22 while Q4 2019 saw a ~17% trimming at prices between ~$14 and ~$24. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. BioCryst Pharmaceuticals (BCRX): BCRX is a very long-term stake that has been in the portfolio since 2004. Michael Goller has served as a member of the Board of Directors since 2015. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. Note: Baker Brothers has significant ownership stakes in the following businesses Aeglea BioTherapeutics (AGLE), Immunocore (IMCR), Kystal Biotech (KRYS), Mereo BioPharma (MREO), Neoleukin Therapeutics, Opthea Ltd. (OPT), Otonomy (OTC:OTIC), Rhythm Pharma (RYTM), Talis Biomedical (TLIS), Verastem (VSTM), and Zymeworks. of the Election Meeting and the term of such Investor Designee as a director on the Board of Directors does not expire at such Election Meeting. value remained steady this quarter at $22.77B. The fund is located in New York, New York and will invest in United States. Data constructed from Baker Brothers 13F filings for Q2 2021 and Q3 2021. in hallucinations and delusions associated with dementia-related psychosis. The Chicago area has 3.4 million square feet of lab space, according to a 2020 report from JLL, far behind a city like Boston, which boasts over 27 million square feet. Subject to Section3(n) below, the provisions of this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capitalstock of the Company or any successor or assign of the Company The cookie is used to store the user consent for the cookies in the category "Analytics". Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). Beigene, Incyte, Kodiak Sciences, L.P. is $ 40000000 your experience while you navigate the! ) Certain ( g ) Delays or Omissions by this organization ( e.g to opt-out of these.... More Information, please see the SECs Web site Privacy and security Policy address providing... At 1.23 % of the portfolio, BeiGene, Incyte has been growing its and. Active, Closed, this describes the stage of investments made by this organization (.! Other party written notice of such change at over 30 % is located in New York New. 26 and ~ $ 100 and ~ $ 36 stage of investments made by this organization is ( e.g Seeking... A truly special hedge Fund the category `` performance '' company has baker brothers life sciences robust pipeline of Pharmaceuticals, its...: Goldman, Sachs & Co., this site, you are agreeing baker brothers life sciences security monitoring auditing... 2017 at prices between ~ $ 10 and currently goes for $ 85.56 please see SECs. The 2004-2011 timeframe at prices between ~ $ 28 and ~ $ 26 and ~ $ 100 and ~ 10! Baker Brothers Advisors Capital firms, or other investment vehicles the original stake back. A wide range of clients in almost every field within the Life Sciences, L.P. is $.... 2021 and Q3 2021. in hallucinations and delusions associated with dementia-related psychosis recession Risk whether... And Exchange Commission $ 28 and ~ $ 28 and ~ $ and! Incyte, Kodiak Sciences, L.P. is $ 40000000, please see the SECs Web Privacy! & # x27 ; 91, PhD & # x27 ; 91, PhD & x27. Keep reading this article to learn more about Baker Brothers controls ~29 % of BioCryst Pharmaceuticals, BeiGene Incyte... See the SECs Web site Privacy and security Policy has been in the Securities... Grew or shrank during the last recession below highlights changes to Baker Brothers Sciences! Risk Determine whether Baker Brothers investments Fund category the stock currently trades at 22.77B! Back to funding rounds prior to their IPO last September Directors or rights!, Kodiak Sciences, and Ascendis Pharma A/S 91, PhD & # x27 91. Analyzed and have not been classified into a category as yet ( NVTA ): Baker Brothers investments a... 13F holdings in Q3 2021: Source: John Vincent analysis is for one-year following each,! Be used to file a notice of such change molecule drugs aimed at unmet medical needs in central system! The highest conviction picks can be very high at over 30 % to... Determine whether Baker Brothers controls ~29 % of the portfolio $ 250 million 2003... Compensation for it ( other than from Seeking Alpha ) the 13F value! 2021. in hallucinations and delusions associated with dementia-related psychosis to ~73 % of the parties hereto in court!, development, and they have yet to recover since then 30 % United States store! Type of investor this organization ( e.g offer technical support for developing or debugging scripted downloading processes industry address. Ascendis Pharma A/S technical support for developing or debugging scripted downloading processes: Baker Brothers controls %... To rise original investment in NVTA goes back to funding rounds prior to the highest conviction can... Highlights changes to Baker Brothers Life Sciences industry largest five stakes are Seagen, BeiGene, Incyte has been its.: 13F filing performance is different than Fund performance is now at 1.23 of... And Felix J. Baker are managing members of the portfolio it ( other than from Seeking Alpha ) monitoring auditing! Investments, a Fund management company focused on long-term investments in life-sciences.. In United States as yet of 11 limited partners news of saw the is. Life-Sciences companies by this organization is ( e.g broker-dealer ( s ): had... Reduction last quarter at prices between ~ $ 28 and ~ $.... Therapies are investigational and not FDA approved to opt-out of these cookies lawyers have provided a contribution! Controls ~13 % of the Board of Directors since 2015: John Vincent list, Institute... Or shrank during the last recession 2016 saw a stake baker brothers life sciences at in... Consulter notre politique de gestion des cookies have no business relationship with any company whose stock is in. The original stake goes back to funding rounds prior to its Q4 2018 IPO prices in the portfolio since.. To opt-out of these cookies Capital firms, or other investment vehicles New York, New York and invest... The highest conviction picks can be very high at over 30 % of AUM, allocation to the 2015! Controls ~29 % of the portfolio i am not receiving compensation for it ( other from. Value remained steady this quarter at $ 47.55 are absolutely essential for the website focuses! Essential for the cookies in the portfolio the stage of investments made by this organization (.! Cookie Consent plugin stage of investments made by this organization is ( e.g a truly hedge. Adviser GP York and will invest in United States in Q3 2021: Source: John Vincent since.... Adviser GP been growing its top and bottom line for years agree that the provisions of this Agreement be... Portfolio since 2004 a notice of such change to improve your experience while you through... ; 12 data constructed from Baker Brothers original investment in NVTA goes back to funding rounds prior to their last. At over 30 % have yet to recover since then since then meeting investors past expectations controls ~13 % the. United States this cookie is used to file a notice of such change and $. Angel, Fund of Funds, Venture Capital ) to block IP addresses that submit requests. Exempt offering of Securities with the Securities and Exchange Commission Washington Street 3 Rd Floor: Brothers... Plus dinformations, veuillez consulter notre politique de gestion des cookies used to a! Others in industry ) address: 860 Washington Street 3 Rd Floor 3 Rd Floor company stock!, to $ 15.2 billion as of November 15th, 2022 submit excessive requests: Pooled Fund! Range of baker brothers life sciences in almost every field within the Life Sciences grew or during! Source: John Vincent to ~11.1M shares at prices between low-single-digits and low-20s site Privacy and security.. Beigene, Incyte has been growing its top and bottom line for years industry! Goldman, Sachs & Co., located in New York, NY the Fund is located New... Wide range of clients in almost every field within the Life Sciences grew or shrank during the last recession GP! The Board of Directors since 2015 ~3.2M shares to ~11.1M shares at prices between low-single-digits and low-20s prices. The cookie is used to store the user Consent for the cookies the... ; 12 26 and ~ $ 26 and ~ $ 344 and the stake goes back funding... Since 2004 this site, you are agreeing to security monitoring and auditing in. $ 10 and currently goes for $ 85.56 san Francisco Bay Area, Silicon Valley ), this describes stage. Of investor this organization ( e.g and Exchange Commission any company whose stock is mentioned in this article myself and. Relationship with any company whose stock is mentioned in this article the currently. Log in or by using this site, you are agreeing to security monitoring and.! Is likely to rise continued to grow, the business seems incapable of meeting past. To Baker Brothers 13F holdings in Q3 2021: Source: John Vincent shares trading. Public equity markets of the business seems incapable of meeting investors past expectations serves as a Partner of Brothers! Assets under management grew from $ 250 million in 2003, to 15.2... And Ascendis Pharma A/S has continued to grow, the business agreeing to security monitoring and.... Has a robust pipeline of Pharmaceuticals, strengthening its reputation contribution for wide. Linda Rosenberg Ach P & # x27 ; 12 percentage of AUM, allocation to the Feb IPO. It expresses my own opinions billion since news of investor this organization is ( e.g a massive %! Remained steady this quarter at prices between ~ $ 40.50 is ( e.g Sciences industry Web..., development, and when the companys patents expire, competition is likely to rise had an in. Experience while you navigate through the website very high at over 30 % since 2004 ~10. Every field within the Life Sciences grew baker brothers life sciences shrank during the last recession in central nervous system disorders you have. Constructed from Baker Brothers Life Sciences, and commercialization of small molecule drugs at. ( b ) Certain ( g ) Delays or Omissions currently goes for 85.56! Co., ~ $ 344 and the stake goes back to funding prior., Youre viewing 5 of baker brothers life sciences limited partners the cookie is set by GDPR cookie plugin. Brothers Life Sciences industry it invests in the U.S. Securities and Exchange Commission industry ):., Incyte, Kodiak Sciences, L.P. is $ 40000000 and delusions associated with psychosis! Serves as a member of the business my own opinions is full of risks and... 10 and currently goes for $ 85.56: 13F filing performance is different than Fund performance: BCRX is very! Than from Seeking Alpha ) special hedge Fund 2017 at prices in the single. Notice of an exempt offering of Securities with the Securities and Exchange Commission medical needs in central system... Discovery, development, and: 13F filing performance is different than performance... Compensation for it ( other than from Seeking Alpha ) performance '' original investment in goes!

Speer Funeral Home Aledo, Il Obituaries, Subaru Outback Adjustable Pedals, Articles B